CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
Industry Trade Show
Not Confirmed
22-25 April, 2025
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
25-30 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels
24 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250424913089/en/LEO-Pharma-Announces-Publication-of-Head-to-Head-DELTA-FORCE-Study-Results-in-The-Lancet
22 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250422320493/en/LEO-Pharma-Survey-Dermatology-Providers-Agree-Chronic-Hand-Eczema-Impacts-Patients-Emotional-Social-and-Occupational-Well-Being
08 Mar 2025
// BUSINESSWIRE
06 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250305690094/en/LEO-Pharma-Survey-Dermatology-Providers-Say-Chronic-Hand-Eczema-Is-Widely-Misunderstood-and-Inadequately-Managed
27 Feb 2025
// BUSINESSWIRE
26 Feb 2025
// BUSINESSWIRE
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8527
Submission : 1990-04-16
Status : Inactive
Type : II
Certificate Number : R1-CEP 2009-309 - Rev 00
Issue Date : 2016-07-29
Type : Chemical
Substance Number : 848
Status : Valid
Registration Number : 218MF10952
Registrant's Address : Industryparken 55, DK-2750 Ballerup
Initial Date of Registration : 2006-11-24
Latest Date of Registration :
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8308
Submission : 1989-11-01
Status : Inactive
Type : II
Certificate Number : R1-CEP 2005-148 - Rev 01
Issue Date : 2013-03-13
Type : Chemical
Substance Number : 2011
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8312
Submission : 1989-11-27
Status : Inactive
Type : II
Certificate Number : R1-CEP 2005-145 - Rev 01
Issue Date : 2013-04-09
Type : Chemical
Substance Number : 2284
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8526
Submission : 1990-04-16
Status : Inactive
Type : II
Certificate Number : R1-CEP 2009-379 - Rev 00
Issue Date : 2016-10-21
Type : Chemical
Substance Number : 798
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8528
Submission : 1990-04-16
Status : Inactive
Type : II
Certificate Number : R0-CEP 2021-040 - Rev 01
Issue Date : 2022-01-19
Type : Chemical
Substance Number : 798
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8529
Submission : 1990-04-16
Status : Inactive
Type : II
Certificate Number : R1-CEP 2009-308 - Rev 02
Issue Date : 2022-01-19
Type : Chemical
Substance Number : 798
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10477
Submission : 1993-09-03
Status : Inactive
Type : II
Certificate Number : R1-CEP 2001-446 - Rev 03
Issue Date : 2020-02-21
Type : Chemical
Substance Number : 333
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
Certificate Number : R1-CEP 2007-286 - Rev 02
Issue Date : 2020-02-18
Type : Chemical and TSE
Substance Number : 1286
Status : Valid
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10514
Submission : 1993-10-08
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10515
Submission : 1993-10-08
Status : Active
Type : II
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: Anzupgo
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2025
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LEO Pharma’s Anzupgo Meets Endpoint in DELTA China Trial
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Product Name : Anzupgo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2025
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: Anzupgo
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 04, 2025
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LEO’s Anzupgo® Achieves Positive DELTA TEEN Trial in Chronic Hand Eczema
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Product Name : Anzupgo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2025
Details:
The partnership aims to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 programs for the potential treatment of patients with inflammatory diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Gilead Sciences
Deal Size: $1,700.0 million Upfront Cash: $250.0 million
Deal Type: Partnership January 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Gilead Sciences
Deal Size : $1,700.0 million
Deal Type : Partnership
Gilead, LEO Pharma Partner to Develop Programs for Inflammatory Diseases
Details : The partnership aims to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 programs for the potential treatment of patients with inflammatory diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $250.0 million
January 11, 2025
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor. It is indicated for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 14, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LEO Pharma’s Anzupgo® (delgocitinib) Cream Achieves Marketing Approval in Switzerland
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor. It is indicated for the treatment of Moderate to Severe Chronic Hand Eczema.
Product Name : LP0133
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2024
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor. It is indicated for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Germany Becomes The First Country to Launch LEO Pharma’s Anzupgo® (delgocitinib) Cream
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor. It is indicated for the treatment of Moderate to Severe Chronic Hand Eczema.
Product Name : LP0133
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Details:
Enstilar is a combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid, indicated as topical treatment of plaque psoriasis.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Brand Name: Enstilar
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2024
Lead Product(s) : Calcipotriol,Betamethasone Dipropionate
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LEO Pharma Submits NDA For Enstilar® For Psoriasis Treatment in China
Details : Enstilar is a combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid, indicated as topical treatment of plaque psoriasis.
Product Name : Enstilar
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2024
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 23, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts LEO Pharma’s NDA for Delgocitinib Cream for Chronic Hand Eczema
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Product Name : LP0133
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Details:
Anzupgo (delgocitinib) cream is a topical pan-JAK inhibitor. It is indicated for the treatment of adult patients with moderate to severe chronic hand eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 23, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EU Approves LEO Pharma’s Anzupgo® For Chronic Hand Eczema in Adults
Details : Anzupgo (delgocitinib) cream is a topical pan-JAK inhibitor. It is indicated for the treatment of adult patients with moderate to severe chronic hand eczema.
Product Name : LP0133
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Details:
Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Brand Name: LP0133
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 25, 2024
Lead Product(s) : Delgocitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LEO Pharma Receives Positive CHMP Opinion for Anzupgo® in Hand Eczema Treatment
Details : Anzupgo (delgocitinib) cream is an investigational, first-in-class, topical pan-JAK inhibitor for CHE. It is under clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.
Product Name : LP0133
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2024
Details:
Adbry (tralokinumab) is an IL-13 inhibitor monoclonal antibody which is approved by USFDA for the treatment for pediatric patients with moderate-to-severe atopic dermatitis.
Lead Product(s): Tralokinumab
Therapeutic Area: Dermatology Brand Name: Adbry
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2024
Lead Product(s) : Tralokinumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Adbry Autoinjector for Atopic Dermatitis
Details : Adbry (tralokinumab) is an IL-13 inhibitor monoclonal antibody which is approved by USFDA for the treatment for pediatric patients with moderate-to-severe atopic dermatitis.
Product Name : Adbry
Product Type : Antibody
Upfront Cash : Inapplicable
June 13, 2024
ABOUT THIS PAGE
Leo Pharma is a supplier offers 26 products (APIs, Excipients or Intermediates).
Find a price of Sodium Fusidate bulk with CEP, JDMF offered by Leo Pharma
Find a price of Calcipotriol bulk with CEP offered by Leo Pharma
Find a price of Fusidic Acid bulk with CEP offered by Leo Pharma
Find a price of Heparin Sodium bulk with CEP offered by Leo Pharma
Find a price of Alfacalcidol bulk with CEP offered by Leo Pharma
Find a price of Calcipotriol bulk with DMF offered by Leo Pharma
Find a price of Heparin Sodium bulk offered by Leo Pharma
Find a price of Sodium Fusidate bulk with CEP offered by Leo Pharma
Find a price of Amdinocillin bulk offered by Leo Pharma
Find a price of Bumetanide bulk offered by Leo Pharma
Find a price of Calcipotriol bulk offered by Leo Pharma
Find a price of Dalteparin sodium bulk offered by Leo Pharma
Find a price of Fusidic Acid bulk offered by Leo Pharma
Find a price of Pivmecilinamo Clorhidrato bulk offered by Leo Pharma
Find a price of Seocalcitol bulk offered by Leo Pharma
Find a price of Sodium Fusidate bulk offered by Leo Pharma
Find a price of Sodium Taurodihydrofusidate bulk offered by Leo Pharma
Find a price of FACILITIES AND OPERATING PROCEDURES bulk offered by Leo Pharma
Find a price of FACILS & CONTROLS USED IN MFGR OF SODIUM FUSIDATE CAPS. bulk offered by Leo Pharma
Find a price of FACILITY FOR THE MANUFACTURE OF EB 1089 IN BALLERUP, DENMARK. bulk offered by Leo Pharma
Find a price of FACILITIES AND OPERATING PROCEDURES IN BALLERUP, DENMARK bulk offered by Leo Pharma
Find a price of MECILLINAM FOR INJECTION bulk offered by Leo Pharma
Find a price of INNOHEP INJECTION 20,000 ANTI-XA IR/ML bulk offered by Leo Pharma
Find a price of PERSONNEL, FACILITIES AND GENERAL OPERATING PROCEDURES bulk offered by Leo Pharma
Find a price of EB 1089 EC-CAPSULES DRUG PRODUCT bulk offered by Leo Pharma
Find a price of Ingenol Mebutate bulk offered by Leo Pharma